Aldoxorubicin
As of the edition of 20 October 2026, Aldoxorubicin is a small molecule: stopped in 2024; acts on TOP2A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 25, 11 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Immune system; Skin and connective tissue
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 companies on route A because of this drug.
Companies on route A for this drug
In the product2 companies are on route A because of Aldoxorubicin.
See the 2 companies on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TOP2A | DNA topoisomerase 2-alpha | P11388 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 4 | 4 | 0 | 0 |
| Phase 2 | 18 | 6 | 1 | 11 |
| Phase 3 | 1 | 1 | 0 | 0 |
| All trials | 25 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Immunitybio | Lead sponsor of trials | 2011 to now |
| LadRx | Lead sponsor of trials |